<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/31BAAEA1-1BCB-4D42-B1B3-4FC2539E6F43"><gtr:id>31BAAEA1-1BCB-4D42-B1B3-4FC2539E6F43</gtr:id><gtr:name>Public Health England</gtr:name><gtr:address><gtr:line1>Porton Down</gtr:line1><gtr:line4>Salisbury</gtr:line4><gtr:line5>Wiltshire</gtr:line5><gtr:postCode>SP4 0JG</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/802F3522-BFFB-4B26-8B3F-E9D688945AC0"><gtr:id>802F3522-BFFB-4B26-8B3F-E9D688945AC0</gtr:id><gtr:name>Ablynx</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/BEB10C4F-5479-4941-B0B4-0CAD06381596"><gtr:id>BEB10C4F-5479-4941-B0B4-0CAD06381596</gtr:id><gtr:name>Veterinary Laboratories Agency</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E27575EF-ABFB-484B-BEEF-53343150A49E"><gtr:id>E27575EF-ABFB-484B-BEEF-53343150A49E</gtr:id><gtr:name>Bill and Melinda Gates Foundation</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/EF6B1E83-9BAD-4ED0-B2A0-5E1A69687339"><gtr:id>EF6B1E83-9BAD-4ED0-B2A0-5E1A69687339</gtr:id><gtr:name>European Commission</gtr:name><gtr:address><gtr:line1>Wetstraat 200 / Rue de la Loi 200</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:department>Immunology and Molecular Pathology</gtr:department><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/31BAAEA1-1BCB-4D42-B1B3-4FC2539E6F43"><gtr:id>31BAAEA1-1BCB-4D42-B1B3-4FC2539E6F43</gtr:id><gtr:name>Public Health England</gtr:name><gtr:address><gtr:line1>Porton Down</gtr:line1><gtr:line4>Salisbury</gtr:line4><gtr:line5>Wiltshire</gtr:line5><gtr:postCode>SP4 0JG</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/802F3522-BFFB-4B26-8B3F-E9D688945AC0"><gtr:id>802F3522-BFFB-4B26-8B3F-E9D688945AC0</gtr:id><gtr:name>Ablynx</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/BEB10C4F-5479-4941-B0B4-0CAD06381596"><gtr:id>BEB10C4F-5479-4941-B0B4-0CAD06381596</gtr:id><gtr:name>Veterinary Laboratories Agency</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E27575EF-ABFB-484B-BEEF-53343150A49E"><gtr:id>E27575EF-ABFB-484B-BEEF-53343150A49E</gtr:id><gtr:name>Bill and Melinda Gates Foundation</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EF6B1E83-9BAD-4ED0-B2A0-5E1A69687339"><gtr:id>EF6B1E83-9BAD-4ED0-B2A0-5E1A69687339</gtr:id><gtr:name>European Commission</gtr:name><gtr:address><gtr:line1>Wetstraat 200 / Rue de la Loi 200</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/3A2D1CFF-D14D-409F-8B2F-D87FFE363AF2"><gtr:id>3A2D1CFF-D14D-409F-8B2F-D87FFE363AF2</gtr:id><gtr:firstName>Robin</gtr:firstName><gtr:surname>Weiss</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/ED7DFA83-26A3-4280-9A85-FEFBEF19AB03"><gtr:id>ED7DFA83-26A3-4280-9A85-FEFBEF19AB03</gtr:id><gtr:firstName>Aine</gtr:firstName><gtr:surname>McKnight</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/EBA4ABCD-0394-4234-8808-94480506F83D"><gtr:id>EBA4ABCD-0394-4234-8808-94480506F83D</gtr:id><gtr:firstName>Mary</gtr:firstName><gtr:surname>Collins</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G8712499"><gtr:id>0D774C2E-B9F1-45E2-BFB5-31DD1E0B134E</gtr:id><gtr:title>HIV humoral immunity and early steps in infection</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G8712499</gtr:grantReference><gtr:abstractText>The AIDS pandemic continues to increase especially in Africa, Asia and Eastern Europe. Therefore, any means of curbing the spread of its cause, the human immunodeficiency virus (HIV) should be actively pursued. We shall analyse the virus-neutralising properties of HIV antibodies in the blood of infected people, and in people and animals immunised with candidate vaccines. Useful antibodies can block HIV infection, whereas harmful antibodies can enhance it. One problem is that the same kind of antibody can act in either way according to the concentration of antibody and a substance called complement in the blood. It is therefore important to ensure that vaccinated persons are not placed at higher risk through enhancing antibodies.

The outer envelope of HIV carries the ABO blood group of the person producing it. We shall investigate whether crossing the blood group barrier might increase or decrease the chance of HIV transmission. Another blood group substance is Duffy antigen present on red cells of everyone except black Africans and their descendants. Some strains of HIV can dock onto Duffy as a receptor and we shall determine whether this matters in HIV infection and development of AIDS.

The different surface molecules or receptors used by HIV to gain entry into cells deliver the virus to different places inside the cell which in turn affects the efficiency of infection of different HIV strains. Using artificially constructed viruses carrying reporter molecules signalling their location we shall determine how the different cellular pathways leading to the nucleus can affect the ability of the virus to establish infection in different cell types in the human body.

We shall link our laboratory-based investigations to data on the course of HIV disease in individuals and on patterns and risks of infection in populations. Moreover, our findings eventually will enable the design of safer, more efficacious vaccines against this deadly virus infection.

Members of the team frequently comment on progress in HIV/AIDS research in the scientific and lay media - see Progress Report.</gtr:abstractText><gtr:technicalSummary>AIDS is a growing public health problem as HIV continues to spread worldwide. (1) Antibodies to the envelope glycoproteins of HIV may neutralise virus infectivity; conversely contain antibodies can enhance infection by changing the conformation of the glycoprotein trimers, or by acting as a bridge to Fc and complement receptors on macrophages. We shall analyse neutralising and enhancing properties of natural and experimental antibodies specific to HIV-1 and HIV-2. It would be particularly unfortunate if HIV vaccines with envelope components elicited enhancing antibodies and sera from vaccinees will be tested in this regard. (2) ABO blood group antigens are expressed on the HIV envelope and we shall determine if naturally occurring anti-A or -B antibodies affect cellular infection and person-to-person transmission. (3) The Duffy antigen receptor for chemokines (DARC) is the major chemokine receptor on red cells, but in most Africans it is absent from red cells though present in other tissues. The role of DARC polymorphism in HIV infection and progression to AIDS will be investigated as we have found that some strains of HIV-1 bind to DARC on red cells and that HIV-2 can utilise DARC as a co-receptor in cell lines. (4) The efficiency of infection after HIV penetration depends on which cellular compartment HIV replicative complexes are delivered to. This will be analysed with HIV vector constructs with respect to entry via chemokine, Fc and complement receptors.</gtr:technicalSummary><gtr:fund><gtr:end>2008-09-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>1987-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>8224943</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Public Health England</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>HPA Centre for Infections</gtr:description><gtr:id>7B51741D-472F-4B2E-BEA2-67825D17014C</gtr:id><gtr:impact>The complementation of the expertise at UCL supported by this grant and that of virologists and epidemiologists at the HPA CfI have resulted in useful outputs and outcomes that would not have been possible either organisation acting alone. 19453415</gtr:impact><gtr:outcomeId>AA729E3B98B-1</gtr:outcomeId><gtr:partnerContribution>Each organisation has paid for the aspects of the research conducted within its own laboratories. The intellectual and practical contributions have been synergistic rather than additive.</gtr:partnerContribution><gtr:piContribution>We invented a novel pseudotype-based neutralization assay for antibodies to H5N1 influenza virus and compared the titres of selected, blinded sets of sera and monoclonal antibodies which had been characterized by traditional techniques at the CfI.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Veterinary Laboratories Agency</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>DEFRA Vetinary Laboratories Agency (VLA)</gtr:description><gtr:id>67BBFBBC-8967-4C05-84F7-8334EAE46079</gtr:id><gtr:impact>The complementation of the expertise at UCL supported by this grant and that of virologists and epidemiologists at the VLA have resulted in useful outputs and outcomes that would not have been possible either organisation acting alone. 19787037 18753230</gtr:impact><gtr:outcomeId>550E37E7B90-1</gtr:outcomeId><gtr:partnerContribution>Each organisation has paid for the aspects of the research conducted within its own laboratories. The intellectual and practical contributions have been synergistic rather than additive.</gtr:partnerContribution><gtr:piContribution>Our rabies and lyssavirus research is conducted in close collaboration with colleagues at the VLA.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>London Centre for Nanotechnology</gtr:department><gtr:description>Multi-Marker Nanosensors for HIV</gtr:description><gtr:id>15A0EF55-DE6E-4892-82ED-D969F0B3FA49</gtr:id><gtr:impact>Fostering inter-discplinary research</gtr:impact><gtr:outcomeId>B78174BD2F1-1</gtr:outcomeId><gtr:piContribution>This is an EPSRC funded collaboration to develop novel nanosensors of HIV and clinical parameters of HIV infection for eventual use in developing countries. Our contribution is to develop reagents including llama VHH for the detection of HIV antigens in clinical samples.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Ablynx</gtr:collaboratingOrganisation><gtr:country>Belgium, Kingdom of</gtr:country><gtr:description>Llama nanobodies directed against influenza</gtr:description><gtr:id>BAA3A862-CAED-4B72-BACA-54D75A28DC92</gtr:id><gtr:impact>Several llama VHH which potently neutralize rabies virus or H5N1 influenza A virus were isolated and which promise to have diagnostic or thearapeutic applications. A paper has been submitted for publication.</gtr:impact><gtr:outcomeId>CD18C5C9B6D-1</gtr:outcomeId><gtr:partnerContribution>It has allowed us to broaden our research on neutralizing llama VHH to dangerous viral pathogens other than HIV.</gtr:partnerContribution><gtr:piContribution>We have developed HIV-based pseudotype viruses bearing the envelope glycoproteins of dangerous viral pathogens such as rabies virus and H5N1 influenza virus to provide sensitive screening and analytical methods for detecting neutralizing antibodies.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Bill and Melinda Gates Foundation</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Vaccine-induced protective cross neutralization of HIV-1</gtr:description><gtr:id>16AD4915-22BC-4D25-9079-1F7713545341</gtr:id><gtr:impact>In addition to the llama antibodies noted in 2.6, We have helped to characterize broadly neutralizing human monoclonal antibodies isolated from immortalised memory B cells from HIV-infected patients. A paper in press will be reported next year.</gtr:impact><gtr:outcomeId>48148C5C35C-1</gtr:outcomeId><gtr:partnerContribution>This grant on which I am PI supports a consortium of academic and bio-tech company researchers as part of the Foundation's Collaboration on AIDS Vaccine Discovery (CAVD). We are contributing to the isolation and characterization of monoclonal antibodies that neutralize HIV-1 infectivity, and to the design of candidate immunogens to elicit protective humoral immunity.</gtr:partnerContribution><gtr:piContribution>Our MRC funded work pioneering the development of llama single chain antibody fragments contributed to this collaboration.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>European Commission</gtr:collaboratingOrganisation><gtr:country>European Union (EU)</gtr:country><gtr:description>European Vaccines and Microbicides Enterprise</gtr:description><gtr:id>B1FE0211-71C5-41A4-881C-0AC1F2FE7669</gtr:id><gtr:impact>18977141</gtr:impact><gtr:outcomeId>084D7DEA00A-1</gtr:outcomeId><gtr:piContribution>Without our MRC grant we would not have been able to contribute our know how and material llama VHH anitbodies to this collaboration. The llama VHH are helpful both for exploitation as a potential microbicide and as a tool in vaccine design.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Interviews by journalists</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:id>2DD673E6-21EA-4E09-B84F-4CECEAF23655</gtr:id><gtr:impact>I am frequently telephoned or interviewed by journalists and television and radio commentators about HIV/AIDS including our own research contributions.

The most notable impact is that leading journalists know whom to approach for reliable and sensible opinions on advances in this field of medical research.</gtr:impact><gtr:outcomeId>61C60D04B9C</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2006,2007,2008,2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>International AIDS Vaccine Conference Cape Town</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:id>5A2EA990-69CE-4929-915B-CB59823FD4F9</gtr:id><gtr:impact>We helped to persuade parliamentarians and two ministers in the South African Government following President Mbeki's resignation that HIV really is the cause of AIDS.

Since 2008 the South African Government has approved the introduction of anti-retroviral therapy for people living with HIV.</gtr:impact><gtr:outcomeId>EEC7371C95B</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/parliamentarians</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Royal Institution</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>C4C12118-3F2D-4E56-8444-99B16391EE3B</gtr:id><gtr:impact>I described the problems and challenges in developing an HIV/AIDS vaccine.

Not known</gtr:impact><gtr:outcomeId>A1314E284D2</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2007</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>School visit to lab</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:id>81D6B7F7-CE5E-48B0-81D5-F9A8542178B4</gtr:id><gtr:impact>School children and their teachers spent a morning learning about germs in a programme that we called &amp;quot;Flu and Poo&amp;quot;.

The children learnt the importance of washing their hands!</gtr:impact><gtr:outcomeId>168DE107833</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2006</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>100000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Research Grant (G0600369)</gtr:description><gtr:end>2008-05-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>8ED99E52-0354-41FF-B7E7-C65B75E1CF65</gtr:id><gtr:outcomeId>4300D8C97050</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>266000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Clinical Research Training Fellowship (G0701352)</gtr:description><gtr:end>2011-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>4DD0E335-4107-44AB-A67E-38A3EEB3AA70</gtr:id><gtr:outcomeId>2B7B25143C30</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>200000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>European Vaccines and Microbicides Enterprise</gtr:description><gtr:end>2011-12-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>FCCB512F-BF69-4B13-A111-59D6DC8611C9</gtr:id><gtr:outcomeId>1915F82CEEE0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>14000000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Gates funding (Vaccine-induced protective cross neutralization of HIV-1)</gtr:description><gtr:end>2012-06-02</gtr:end><gtr:fundingOrg>Bill and Melinda Gates Foundation</gtr:fundingOrg><gtr:id>C5FAB5AB-78A1-4275-91CA-F03561D05FD2</gtr:id><gtr:outcomeId>32E232341EE0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2006-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>400000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>EPSRC EP/G062064/1 Multi-Marker Nanosensors for HIV</gtr:description><gtr:end>2011-04-02</gtr:end><gtr:fundingOrg>Engineering and Physical Sciences Research Council (EPSRC)</gtr:fundingOrg><gtr:fundingRef>EP/G062064/1</gtr:fundingRef><gtr:id>05B43AED-4CDC-45C5-8092-DA84574084F3</gtr:id><gtr:outcomeId>899A4FA5AFE0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-05-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>A patent was filed by our Collaborator, Ablynx NV, with two UCL staff as inventors but he company subsequently abandoned the maintenance of this filing because neither the company nor UCL Business was prepared to foot the bill.</gtr:description><gtr:grantRef>G8712499</gtr:grantRef><gtr:id>8C08676B-712D-460F-AA25-B735491D5E95</gtr:id><gtr:impact>PATENT ABANDONED

See impact under 7.6</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>1A094324C4E</gtr:outcomeId><gtr:patentId>WO2009147248</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Llama nanobodies</gtr:title><gtr:yearProtectionGranted>2009</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Anti-retroviral therapy</gtr:description><gtr:geographicReach>Africa</gtr:geographicReach><gtr:guidelineTitle>Treatment of HIV infection in South Africa</gtr:guidelineTitle><gtr:id>558C4426-D914-4202-9ED0-CBE943DE7297</gtr:id><gtr:impact>During the period that the South African Government questioned the link between HIV infection and AIDS, it is estimated that approximately 350,000 HIV infected South Africans died as a result of their infection who would have lived if given therapy. This disasterous policy has now been reversed.</gtr:impact><gtr:outcomeId>BE38EE3AA8A</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Select Committee of Parlament</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>44208C5E-8648-4A45-9D9A-B44D23F660FD</gtr:id><gtr:impact>The DoH is supposed to heed Select Committees.</gtr:impact><gtr:outcomeId>9D25E115801</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>The llama VHH are single chain antibody fragments that have the binding capacity and specificity of antibodies.</gtr:description><gtr:id>48902198-E927-4F25-91B9-820AD5105408</gtr:id><gtr:impact>They were added to international repositories from which other researchers could gain access to these reagents. They also form part of international panels of HIV neutralizing antibodies used for research and biological standardization.</gtr:impact><gtr:outcomeId>536BB97EB16</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Llama antibody (VHH) fragments</gtr:title><gtr:type>Antibody</gtr:type><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>We have cloned and expressed env genes from diverse isolates of clade C viruses obtained from the UK and African countries. This has helped to fill a gap in internationally available panels of HIV-1 strains for vaccine research.</gtr:description><gtr:id>25088D4A-2047-452F-84DE-D54A8A29C670</gtr:id><gtr:impact>A subset of env genes have been included in standardized panels of HIV-1 pseudovirses proveded to the interational research community through the Collaboration of AIDS Vaccine Discovery (CAVD) of the Bill &amp;amp; Melinda Gates Foundation.</gtr:impact><gtr:outcomeId>458FCCF9323</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Clade C HIV-1 envelope genes</gtr:title><gtr:type>Database/Collection of Data/Biological Samples</gtr:type><gtr:yearFirstProvided>2007</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>We have exploited technology that we developed for the study of HIV-1 to develop reagents which provide highly sensitive and specific assays for neutralizing antibodies of H5N1 influenza and of rabies and related lyssaviruses without the need for Containment Level 4 facilities. These reagents greatly reduce the pressure on CL4 laboratories.</gtr:description><gtr:id>EAA16A44-4AA9-4B00-A0F3-34B8CF8FEC37</gtr:id><gtr:impact>1. Some pharmacutical companies involved in vaccine development (eg Novartis, Baxter) have adopted our reagents and this method for vaccine R&amp;amp;D. Some public helath laboratories (including our collaborations with the HPA and the VLA) have also taken on this technique. Because I described this technique at an open MRC workshop on avian influenza, our placement of this knowledge into the public domain nulified a subsequently filed patent claim that threatened to impede the adoption of this technique for the benefit of global health. 2. This technique is also proving to be of practicle use for serological surveillance of field samples including those from Africa as described under grant G0801176.</gtr:impact><gtr:outcomeId>F8C93DDA32D</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Pseudoviruses of H5N1 influenza and rabies viruses</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2006</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Single chain llama antibody fragments (VHH) are small 12-15 Kd proteins that have the antigen combining properties of antibodies. Using phage display techniques we isolated three VHH with broadly cross-neutralizing properties for many HIV-1 stains derived from different clades. These are useful research materials.</gtr:description><gtr:id>5EABACF3-122C-4159-A8A6-B3E4C855D3B5</gtr:id><gtr:impact>They have been banked in two international AIDS reagent repositories and the HIV research community has made several requests to use these reagents.</gtr:impact><gtr:outcomeId>CD0C7B17E74</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Llama monoclonal antibodies to HIV</gtr:title><gtr:type>Antibody</gtr:type><gtr:yearFirstProvided>2008</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>EDA4C570-42D6-43BA-AB63-86693743D1EF</gtr:id><gtr:title>On viruses, discovery, and recognition.</gtr:title><gtr:parentPublicationTitle>Cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9534aa604573ebb664d3a86545b1f41b"><gtr:id>9534aa604573ebb664d3a86545b1f41b</gtr:id><gtr:otherNames>Weiss RA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0092-8674</gtr:issn><gtr:outcomeId>5B921076C50</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>79EE2208-823B-4684-A983-F0F868F061EC</gtr:id><gtr:title>Clade specific neutralising vaccines for HIV: an appropriate target?</gtr:title><gtr:parentPublicationTitle>Current HIV research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b53011b36c5249099e9db2c200af5a28"><gtr:id>b53011b36c5249099e9db2c200af5a28</gtr:id><gtr:otherNames>McKnight A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1570-162X</gtr:issn><gtr:outcomeId>7528BED99C5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5F0F5BC9-8B09-418C-AD66-28FAAC822870</gtr:id><gtr:title>A prospective study of Kaposi's sarcoma-associated herpesvirus and Epstein-Barr virus in adults with human immunodeficiency virus-1.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9f3950dbc2fcc3f7ee4e0518e9e7996a"><gtr:id>9f3950dbc2fcc3f7ee4e0518e9e7996a</gtr:id><gtr:otherNames>Newton R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>9B5A120B78E</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>018CD56A-E138-49FA-A42F-A64F0F9199B6</gtr:id><gtr:title>HIV blocking antibodies following immunisation with chimaeric peptides coding a short N-terminal sequence of the CCR5 receptor.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bc21936dc324cbd71716009b3faad149"><gtr:id>bc21936dc324cbd71716009b3faad149</gtr:id><gtr:otherNames>Chain BM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>58B30F10031</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D9A3AC6C-58B7-4D34-8EDD-9C4FE4D5A01C</gtr:id><gtr:title>Duffy antigen receptor for chemokines mediates trans-infection of HIV-1 from red blood cells to target cells and affects HIV-AIDS susceptibility.</gtr:title><gtr:parentPublicationTitle>Cell host &amp; microbe</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1a4067e6593d9f0794e19b887076021f"><gtr:id>1a4067e6593d9f0794e19b887076021f</gtr:id><gtr:otherNames>He W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1931-3128</gtr:issn><gtr:outcomeId>CFEA16A05F2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F0F843B7-5F07-4F46-B190-BEE626B30672</gtr:id><gtr:title>Clonal origin and evolution of a transmissible cancer.</gtr:title><gtr:parentPublicationTitle>Cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2e3e5b0f4f8a295b3ffe235e948039a9"><gtr:id>2e3e5b0f4f8a295b3ffe235e948039a9</gtr:id><gtr:otherNames>Murgia C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0092-8674</gtr:issn><gtr:outcomeId>8344C91EFB4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C52B7D43-6905-4C91-842D-C8A0F9DAF78C</gtr:id><gtr:title>Llama antibody fragments with cross-subtype human immunodeficiency virus type 1 (HIV-1)-neutralizing properties and high affinity for HIV-1 gp120.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/93a451bf1b348d74a82a3f39eded8f8a"><gtr:id>93a451bf1b348d74a82a3f39eded8f8a</gtr:id><gtr:otherNames>Forsman A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>21010B69312</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>29DB61F7-1629-45AC-96BA-63F5E4F18A17</gtr:id><gtr:title>Special anniversary review: twenty-five years of human immunodeficiency virus research: successes and challenges.</gtr:title><gtr:parentPublicationTitle>Clinical and experimental immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9534aa604573ebb664d3a86545b1f41b"><gtr:id>9534aa604573ebb664d3a86545b1f41b</gtr:id><gtr:otherNames>Weiss RA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0009-9104</gtr:issn><gtr:outcomeId>B48BF4E0585</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>63C98239-C765-48A0-BB71-1BC6E8FB4C4A</gtr:id><gtr:title>A phase I, randomized study of combined IL-2 and therapeutic immunisation with antiretroviral therapy.</gtr:title><gtr:parentPublicationTitle>Journal of immune based therapies and vaccines</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/343ad531546cd309e16b6dc410f86821"><gtr:id>343ad531546cd309e16b6dc410f86821</gtr:id><gtr:otherNames>Hardy GA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1476-8518</gtr:issn><gtr:outcomeId>4ED53E95BFA</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C610A287-ECD6-4450-A46D-4EB04C4DBB4C</gtr:id><gtr:title>Why is HIV a pathogen?</gtr:title><gtr:parentPublicationTitle>Trends in microbiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/93a451bf1b348d74a82a3f39eded8f8a"><gtr:id>93a451bf1b348d74a82a3f39eded8f8a</gtr:id><gtr:otherNames>Forsman A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0966-842X</gtr:issn><gtr:outcomeId>80343613F2F</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C377A329-BA1A-4F71-98C3-E1606DACF9A7</gtr:id><gtr:title>Humoral immunity to HIV-1: neutralisation and antibody effector functions.</gtr:title><gtr:parentPublicationTitle>Trends in microbiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3d2f75f418faedb6fd9153213e83fa04"><gtr:id>3d2f75f418faedb6fd9153213e83fa04</gtr:id><gtr:otherNames>Willey S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0966-842X</gtr:issn><gtr:outcomeId>3A457C63284</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>136E8993-9522-4D66-89FD-2C8634690D15</gtr:id><gtr:title>Investigating antibody neutralization of lyssaviruses using lentiviral pseudotypes: a cross-species comparison.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/654a6d10a06f182dd8f0d98e126c3340"><gtr:id>654a6d10a06f182dd8f0d98e126c3340</gtr:id><gtr:otherNames>Wright E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn><gtr:outcomeId>67FB3064A19</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>417D328A-AC9C-4CF3-A481-7395317BA951</gtr:id><gtr:title>Duffy-null-associated low neutrophil counts influence HIV-1 susceptibility in high-risk South African black women.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b8f24d249ab4748fb2a46da8d1fcbbe9"><gtr:id>b8f24d249ab4748fb2a46da8d1fcbbe9</gtr:id><gtr:otherNames>Ramsuran V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>kpq9sZCgd63</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1B421086-B880-47C8-BCF4-47461FE89442</gtr:id><gtr:title>Mapping the immune response to the outer domain of a human immunodeficiency virus-1 clade C gp120.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/36e6bd83dfd373c441dfe6211f736a6c"><gtr:id>36e6bd83dfd373c441dfe6211f736a6c</gtr:id><gtr:otherNames>Chen H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn><gtr:outcomeId>9EB4A837FAE</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2A030F3A-3DFA-4AB9-A0C1-11B2003D3549</gtr:id><gtr:title>Novel envelope determinants for CCR3 use by human immunodeficiency virus.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/606c1ab317e343afbff57b6a1a7a52e8"><gtr:id>606c1ab317e343afbff57b6a1a7a52e8</gtr:id><gtr:otherNames>Aasa-Chapman MM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>D27B48FC86C</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ACC895CD-C97F-4E2C-AE57-9F873A7B7C30</gtr:id><gtr:title>Human RNA &amp;quot;rumor&amp;quot; viruses: the search for novel human retroviruses in chronic disease.</gtr:title><gtr:parentPublicationTitle>Microbiology and molecular biology reviews : MMBR</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/370a569ba87bf961f85f31a678604cc7"><gtr:id>370a569ba87bf961f85f31a678604cc7</gtr:id><gtr:otherNames>Voisset C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1092-2172</gtr:issn><gtr:outcomeId>9296F6C3F39</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9569FC2B-72E7-490B-97CE-18E758371FFC</gtr:id><gtr:title>Origins of HIV and the evolution of resistance to AIDS.</gtr:title><gtr:parentPublicationTitle>Science (New York, N.Y.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6d2866163f2ae2284c4783f80104c728"><gtr:id>6d2866163f2ae2284c4783f80104c728</gtr:id><gtr:otherNames>Heeney JL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0036-8075</gtr:issn><gtr:outcomeId>E5EDB1A37E2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2AA137EC-1667-46BC-86B5-8AA267AAF652</gtr:id><gtr:title>A sensitive retroviral pseudotype assay for influenza H5N1-neutralizing antibodies.</gtr:title><gtr:parentPublicationTitle>Influenza and other respiratory viruses</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/119090675276fd0e791054da5c3c73f5"><gtr:id>119090675276fd0e791054da5c3c73f5</gtr:id><gtr:otherNames>Temperton NJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1750-2640</gtr:issn><gtr:outcomeId>8F0BD9D83B4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8440E0B5-B3E5-4B44-B6C5-8AC79A4C4AB0</gtr:id><gtr:title>Primary CCR5 only using HIV-1 isolates does not accurately represent the in vivo replicating quasi-species.</gtr:title><gtr:parentPublicationTitle>Virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/606c1ab317e343afbff57b6a1a7a52e8"><gtr:id>606c1ab317e343afbff57b6a1a7a52e8</gtr:id><gtr:otherNames>Aasa-Chapman MM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0042-6822</gtr:issn><gtr:outcomeId>D806987888A</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G8712499</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>75</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>CDB856E6-DF2D-4D96-88BD-1CC96FE277EF</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>2.2  Factors relating to physical environment</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>